• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

    6/10/24 1:00:00 AM ET
    $FLGT
    $NEO
    Medical Specialities
    Health Care
    Precision Instruments
    Health Care
    Get the next $FLGT alert in real time by email

    PRESS RELEASE - 10/06/2024, 07:00 CEST

    Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing



    Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing.

    Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 years of experience in the diagnostics industry and combines a scientific background with business acumen and strong commercial leadership.

    Dr. Wallar holds a Master's degree in Epidemiology and Biostatistics from Boston University and a PhD in Cancer Epidemiology from UCLA. Previously, Dr. Wallar served as President of Pharma Services Division at NeoGenomics Laboratories (NASDAQ:NEO), a clinical laboratory and pharma services company that is specialized in cancer diagnostic testing. She then moved on to become Senior Vice President and General Manager at Fulgent Genetics (NASDAQ:FLGT), a full-service genomic testing company, where she led sales and business development. Dr. Wallar finally served as Chief Commercial Officer at Flagship Biosciences, a spatial biology and biomarker services company, before joining the Biocartis team.

    Judith Vacchino, PhD as VP Global Marketing: Judith Vacchino was appointed as Biocartis' VP Global Marketing on 15 April 2024 and will be leading global marketing, market management and product management. Dr. Vacchino brings more than 20 years of experience in the diagnostics industry to the table, combining her strong scientific knowledge with marketing expertise.

    Dr. Vacchino holds a Bachelor's degree in Chemistry from Rutgers University and a PhD in Biophysical Chemistry from Stanford University. Before starting at Biocartis, Dr. Vacchino spent nearly 15 years at Genomic Health where she drove the adoption of the Oncotype DX® Breast Recurrence Score to standard of care. After the acquisition of Genomic Health by Exact Sciences, a company specializing in the detection of early-stage cancers, Dr. Vacchino was appointed Senior Director of HCP Marketing for Oncology and Urology products. Most recently, Dr. Vacchino was Senior Director of Product Marketing at GRAIL, a company whose mission it is to detect cancer early, where she led the clinic marketing strategy for Galleri®, the first commercially available multi-cancer early detection test.

    Roger Moody, Chief Executive Officer of Biocartis, commented: "I am extremely pleased to welcome Gina and Judith to the Biocartis team. With more than four decades of experience in the diagnostics field between the two of them, they arrive at Biocartis with backpacks full of useful skills and incredible know-how that can only make us better positioned to achieve new heights of success. We look forward to leveraging their experience to revolutionize diagnostics and solidify our position in the US market."

    ----- END -----

    More information:

    www.biocartis.com

    [email protected]

    About Biocartis

    With its revolutionary and proprietary Idylla™ Platform, Biocartis aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, convenient, fast and suitable for any lab. The Idylla™ Platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions. Idylla™'s continuously expanding menu of molecular diagnostic tests addresses key unmet clinical needs, with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal, lung, breast, thyroid and liver cancer. More information: www.biocartis.com. Follow us on X (Twitter): @Biocartis.

    Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. © June 2024, Biocartis NV. All rights reserved.



    Primary Logo

    Get the next $FLGT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FLGT
    $NEO

    CompanyDatePrice TargetRatingAnalyst
    NeoGenomics Inc.
    $NEO
    5/15/2025Neutral
    Guggenheim
    NeoGenomics Inc.
    $NEO
    4/30/2025$9.00Outperform → Market Perform
    Leerink Partners
    NeoGenomics Inc.
    $NEO
    1/13/2025Buy → Hold
    The Benchmark Company
    NeoGenomics Inc.
    $NEO
    12/10/2024$22.00Buy
    Jefferies
    NeoGenomics Inc.
    $NEO
    5/1/2024$26.00Buy
    Craig Hallum
    NeoGenomics Inc.
    $NEO
    12/29/2023$25.00 → $21.00Buy
    BTIG Research
    Fulgent Genetics Inc.
    $FLGT
    12/7/2023$35.00Neutral
    UBS
    NeoGenomics Inc.
    $NEO
    8/21/2023$18.00Equal-Weight → Overweight
    Stephens
    More analyst ratings

    $FLGT
    $NEO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

      NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic)

      7/1/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

      NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). These new options can provide faster, actionable insights to help physicians navigate complex treatment decisions more confidently. PanTracer Tissue evaluates over 500 cancer-related genes and aligns with clinical guidelines, covering key biomarkers recommended for therapy selection and additional genomic insights for clinical trial enrollment. Results may be delivered in as little as 8 days, enabli

      6/30/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

      NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue a

      6/24/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care

    $FLGT
    $NEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Green Marjorie C

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      6/24/25 4:06:13 PM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form 3 filed by new insider Green Marjorie C

      3 - NEOGENOMICS INC (0001077183) (Issuer)

      6/24/25 4:05:24 PM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Hsieh Ming

      4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

      6/11/25 4:30:58 PM ET
      $FLGT
      Medical Specialities
      Health Care

    $FLGT
    $NEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kelly Michael Aaron bought $38,000 worth of shares (5,000 units at $7.60) (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/28/25 4:07:40 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Pres & Chief Operating Officer Stone Warren converted options into 9,613 shares, covered exercise/tax liability with 2,341 shares and bought $48,895 worth of shares (5,700 units at $8.58), increasing direct ownership by 14% to 108,280 units (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/13/25 4:05:28 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Director Tetrault Lynn A. bought $56,974 worth of shares (7,000 units at $8.14) (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/9/25 5:26:57 PM ET
      $NEO
      Precision Instruments
      Health Care

    $FLGT
    $NEO
    SEC Filings

    See more
    • NeoGenomics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NEOGENOMICS INC (0001077183) (Filer)

      6/24/25 7:10:30 AM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form S-8 filed by NeoGenomics Inc.

      S-8 - NEOGENOMICS INC (0001077183) (Filer)

      6/16/25 4:27:15 PM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - NEOGENOMICS INC (0001077183) (Filer)

      5/27/25 4:07:12 PM ET
      $NEO
      Precision Instruments
      Health Care

    $FLGT
    $NEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on NeoGenomics

      Guggenheim initiated coverage of NeoGenomics with a rating of Neutral

      5/15/25 8:12:40 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded NeoGenomics from Outperform to Market Perform and set a new price target of $9.00

      4/30/25 8:08:08 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics downgraded by The Benchmark Company

      The Benchmark Company downgraded NeoGenomics from Buy to Hold

      1/13/25 8:42:07 AM ET
      $NEO
      Precision Instruments
      Health Care

    $FLGT
    $NEO
    Financials

    Live finance-specific insights

    See more
    • NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

      NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic)

      7/1/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • Fulgent Reports First Quarter 2025 Financial Results

      Core Revenue of $73.5 million grows 16% year-over-year Reiterating Full Year 2025 Core Revenue Guidance of $310 million Non-GAAP income of $1.2 million, or $0.04 per share; GAAP loss of $11.5 million, or ($0.37) per share Ended Q1 with $814.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.60 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $

      5/2/25 7:00:00 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • NeoGenomics Reports First Quarter 2025 Results

      Consolidated Revenue Increased 8% to $168 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights As Compared To First Quarter 2024 Consolidated revenue increased 8% to $168 million Net loss decreased 4% to $26 million Adjusted EBITDA increased 102% to positive $7 million "Our business is off to a solid start in 2025 with our team delivering a record number of results to patients in the first quarter and improving our adjusted EBITDA by over 100% from prior year," said Ton

      4/29/25 7:30:00 AM ET
      $NEO
      Precision Instruments
      Health Care

    $FLGT
    $NEO
    Leadership Updates

    Live Leadership Updates

    See more
    • NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

      NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue a

      6/24/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

      Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company's current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025. Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible f

      3/18/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance

    $FLGT
    $NEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

      SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

      11/14/24 1:28:29 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Fulgent Genetics Inc.

      SC 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)

      11/5/24 4:46:55 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by NeoGenomics Inc.

      SC 13G - NEOGENOMICS INC (0001077183) (Subject)

      2/14/24 10:04:34 AM ET
      $NEO
      Precision Instruments
      Health Care